RAMP 201

Overview of attention for article published in Journal of Clinical Oncology, July 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 3 news outlets
twitter: 16 X users

bluesky: 3 Bluesky users

Readers on

mendeley: 74 Mendeley

So far, Altmetric has seen 19 X posts from 16 X users, with an upper bound of 77,766 followers.

RT @MarioBalsaMD: 🚨 Fresh in @JCO_ASCO! ENGOT-OV60/RAMP 201: avutometinib (MEK clamp) ± defactinib (FAK inhibitor) in recurrent LGSOC after…

RT @NCCH_MD: RAMP 301 will start soon. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Prim…

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201 https://t.co/KEB1B7mADp #ScientiaVH

RT @NCCH_MD: RAMP 301 will start soon. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Prim…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 15 additional X posts.